---
schema_version: "secwatch.filing_event.v1"
accession: "0001708599-26-000036"
form_type: "8-K"
ticker: "SER"
cik: "0001708599"
company_name: "Serina Therapeutics, Inc."
filed_at: "2026-05-14T20:05:05+00:00"
generated_at: "2026-05-14T20:06:17.138075+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Serina Therapeutics Q1 2026 net loss $6.9M; Phase 1b study of SER-252 underway

## Summary
- Net loss of $6.9M ($0.58 per share) for Q1 2026 vs. $4.8M ($0.49) in Q1 2025.
- R&D expenses $3.2M, G&A $3.1M; total operating expenses $6.3M.
- Cash and equivalents $24.5M at March 31, 2026; additional $5.2M from PIPE in April.
- SER-252 Phase 1b registrational study underway; first patient dosed Feb 2026; TFL data from SAD arm expected H1 2027.
- Closed $21.2M private placement in March/April 2026; Senior Convertible Note amended to remove further borrowing obligations.

## SEC filing metadata
- accession: 0001708599-26-000036
- form_type: 8-K
- ticker: SER
- cik: 0001708599
- company_name: Serina Therapeutics, Inc.
- filed_at: 2026-05-14T20:05:05+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/0001708599-26-000036-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/ser-20260514.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001708599-26-000036
- JSON: https://secwatch.observer/filing/0001708599-26-000036.json
- Plain text: https://secwatch.observer/filing/0001708599-26-000036.txt

## Key facts
- Earnings Releases
  Serina Therapeutics, Inc. reported the first quarter ended March 31, 2026 results: net income $6.9 million, EPS $(0.58) per basic and diluted share.
  - Period: the first quarter ended March 31, 2026
  - Net income: $6.9 million
  - EPS: $(0.58) per basic and diluted share
  - Result: reported results
  source text: Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ PlatformTM drug optimization technology, today reported its financial results for the first quarter ended March 31, 2026, along with key business updates.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1708599/000170859926000036/0001708599-26-000036-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.